You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和鉑醫藥-B(02142.HK):兩項HBM4003 I期試驗完成向首名患者的首次給藥
格隆匯 01-03 18:53

格隆匯1月3日丨和鉑醫藥-B(02142.HK)宣佈,公司在HBM4003臨牀I期試驗中,完成向首名患者就治療晚期肝細胞癌及其他實體瘤以及治療晚期神經內分泌腫瘤及其他實體瘤的兩項首次給藥。HBM4003為公司開發的下一代抗CTLA-4全人源重鏈抗體(HCAb)。本臨牀研究旨在評估綜合使用HBM4003及託瑞帕利單抗(PD-1抗體)對中國肝細胞癌、神經內分泌腫瘤及其他實體瘤患者的安全性、耐受性、藥代動力學╱藥效學及初步療效。

作為產品管線的一部分,公司正在開發HBM4003用於治療多種有大量未獲滿足醫療需求的實體瘤。公司正於中國針對相關適應症開發候選藥物,而肝細胞癌及神經內分泌腫瘤為當中最早展開研究的適應症之一。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account